Recurrence of pulmonary tuberculosis in India: Findings from the 2019-2021 nationwide community-based TB prevalence survey.
Prathiksha GiridharanSriram SelvarajuRaghuram RaoKiran RadeKannan ThiruvengadamSmita AsthanaRakesh BalachandarSampada Dipak BangarAvi Kumar BansalJyothi BhatDebjit ChakrabortyVishal ChopraDasarathi DasShanta DuttaKangjam Rekha DeviSunil KumarAvula LaxmaiahMajor MadhukarAmarendra MahapatraSuman Sundar MohantyChethana RangarajuJyotirmayee TurukKamran ZamanRajendran KrishnanSivakumar ShanmugamNishant KumarRajendra Panduranga JoshiSomashekar NarasimhaiahPadmapriyadarsini ChandrasekaranRaman R GangakhedkarBalram BhargavaPublished in: PloS one (2023)
Recurrent Tuberculosis patients contribute to a significant proportion of TB burden in India. A nationwide survey was conducted during 2019-2021 across India among adults to estimate the prevalence of TB. A total of 322480 individuals were screened and 1402 were having TB. Of this, 381 (27.1%) had recurrent TB. The crude prevalence (95% CI) of recurrent TB was 118 (107-131) per 100,000 population. The median duration between episodes of TB was 24 months. The proportion of drug resistant TB was 11.3% and 3.6% in the recurrent group and new TB patients respectively. Higher prevalence of recurrent TB was observed in elderly, males, malnourished, known diabetics, smokers, and alcohol users. (p<0.001). To prevent TB recurrence, all treated tuberculosis patients must be followed at least for 24 months, with screening for Chest X-ray, liquid culture every 6 months, smoking cessation, alcohol cessation, nutritional interventions and good diabetic management.
Keyphrases
- mycobacterium tuberculosis
- pulmonary tuberculosis
- end stage renal disease
- drug resistant
- smoking cessation
- ejection fraction
- newly diagnosed
- risk factors
- chronic kidney disease
- prognostic factors
- type diabetes
- peritoneal dialysis
- multidrug resistant
- physical activity
- computed tomography
- cross sectional
- weight loss
- human immunodeficiency virus
- insulin resistance
- adipose tissue
- metabolic syndrome
- adverse drug